Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inetetamab, Pyrotinib, and Vinorelbine in HER2+ Metastatic Breast Cancer
NCT05823623Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of inetetamab in breast cancer, sponsored by Jiangsu Provincial People's Hospital. Started Feb 2022; status: recruiting.
02
Drugs
inetetamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05823623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05823623.